Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q99650
UPID:
OSMR_HUMAN
Alternative names:
Interleukin-31 receptor subunit beta
Alternative UPACC:
Q99650; Q6P4E8; Q96QJ6
Background:
The Oncostatin-M-specific receptor subunit beta, also known as Interleukin-31 receptor subunit beta, plays a crucial role in the immune system. It forms a receptor with IL31RA, binding IL31 to activate STAT3 and possibly STAT1 and STAT5, thus transducing OSM-specific signaling events.
Therapeutic significance:
Given its involvement in primary localized cutaneous amyloidosis, understanding the role of Oncostatin-M-specific receptor subunit beta could lead to novel treatments for this condition, which is characterized by localized cutaneous amyloid deposition, leading to skin hyperpigmentation and thickening.